Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registry

Nakaya, Aya; Kohara, Takae; Shibayama, Hirohiko; Onda, Yoshiyuki; Kanda, Junya; Kaneko, Hitomi; Imada, Kazunori; Kida, Toru; Kosugi, Satoru; Ishikawa, Jun; Yamamura, Ryosuke; Shimazu, Yutaka; Tanaka, Hirokazu; Fuchida, Shin‐ichi; Shimura, Yuji; Kiyota, Miki; Wada, Katsuya; Ito, Tomoki; Uoshima, Nobuhiko; Yano, Hideo; Yoshihara, Satoshi; Ohta, Kensuke; Shimazaki, Chihiro; Hino, Masayuki; Takaori‐Kondo, Akifumi; Kuroda, Junya; Matsumura, Itaru; Nomura, Shosaku; Investigators, Kansai Myeloma Forum

doi:10.1007/s12185-020-02996-6

Cited by 4 publications

(13 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SCT was the most used therapeutic strategy in young MM in the Nakaya series [39]. Similar to our case, chemotherapy was initiated waiting for SCT and no accurate statement regarding its prognosis was made.…”

Section: Discussionsupporting

confidence: 52%

“…According to the series reported by Bladé and Nakaya, the most common CRAB symptom (hypercalcemia, renal insufficiency, anemia, bone lesion) in young MM was bone lesions. Its incidence ranges between 69% and 76% [7,39]. The contradictory calcemic rate somewhat increased.…”

Section: Discussionmentioning

confidence: 99%

“…The M protein is used as a diagnostic tool for the clone of plasma cell identification, as a tumor marker to follow the course of the MM and response to therapy [20,41]. Similar to the elderly, MM the most frequently secreted M protein was IgG, followed by Ig A, and a light chain which was found in 41%, 45%, and 21% of series; respectively [7,39]. Nevertheless, some patients have no detectable immunoglobin within serum or urine.…”

Section: Discussionmentioning

confidence: 99%

“…According to the International Staging System (ISS), stages I and II are most frequent at diagnosis time in young MM. However, stage III of the ISS is rare [6,39]. Indeed, 68% of the patients in the Jurczyszyn cohort were diagnosed in stage I of ISS [34].…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Non-secretory myeloma in young man mimicking the Gorham disease: case report and the literature review

Ferjani

M²,

Affess

et al. 2022

Romanian Journal of Internal Medicine

View full text Add to dashboard Cite

Multiple myeloma is a neoplasm of plasma cells affecting mostly the elderly with incidence peaks between 60 and 70 years. This disease is exceedingly rare in younger people, especially in adults under 30-year-old. Non-secretory multiple myeloma accounts for 1–5% of all cases of multiple myeloma. It is also a rare condition in young adult patients, and only six cases have been reported [1]. We herein describe a rare case of non-secretory myeloma in a 22- year-old male, explaining from chest wall pain, without general manifestation. Plain radiography and CT scans revealed diffuse osteolytic lesion mimicking the Gorham disease. A bone marrow biopsy was conducted, revealing the diagnosis of myeloma.

show abstract

Section: Discussionsupporting

confidence: 52%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Non-secretory myeloma in young man mimicking the Gorham disease: case report and the literature review

Ferjani

M²,

Affess

et al. 2022

Romanian Journal of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…A Japanese registry study identified 26 symptomatic MM patients aged 16-39 years with a 5-year OS of 71%. 6 Another multiinstitutional case-control study that compared 173 younger patients (21-40 years of age) to patients aged 41-60 years found better 10-year OS in the younger group (67% vs. 39%). 5 Only 83 patients (48%) in the younger age group received an auto-HCT.…”

Section: Discussionmentioning

confidence: 99%

Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up‐front autologous stem cell transplant

2023

View full text Add to dashboard Cite

SummaryMultiple myeloma (MM) primarily affects older patients. There are scarce data on the outcomes of young adults undergoing autologous transplantation (auto‐HCT). In this single‐centre analysis, we included 117 younger patients, with a median age of 37 years (range 22–40) at transplant. Seventeen (15%) patients had high‐risk cytogenetics. Before transplant, 10% of patients achieved ≥CR and 44% achieved ≥VGPR. At best post‐transplant response, 56% and 77% of patients achieved ≥CR and ≥VGPR respectively. With a median follow‐up for survivors of 72.6 months (range 0.9–238.0), median PFS and OS were 43.1 months (95% CI 31.2–65.0) and 146.6 months (95% CI 100.0–208.1) respectively. Patients who underwent auto‐HCT after 2010 had better median PFS (84.9 months vs. 28.2 months, p < 0.001) and OS (NR vs. 91.8 months, p < 0.001) compared with those transplanted earlier. In multi‐variate analysis, achieving ≥CR as best post‐transplant response was associated with improved PFS (HR [95% CI] 0.55 [0.32–0.95], p = 0.032), while achieving ≥VGPR was predictive of superior OS (0.32 [0.16–0.62], p < 0.001). Three patients (3%) developed a second primary malignancy. Younger MM patients had durable survival after auto‐HCT, which further improved after the availability of novel anti‐myeloma drugs in recent years. Depth of response following transplant remains a key predictor of survival.

show abstract

Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study

Tanguay,

Roy,

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

BackgroundYoung patients ≤ 50 years old with multiple myeloma (MM) account for about 10% of cases and are underrepresented in the literature.MethodsWe explored disease characteristics, treatments, and outcomes following modern therapies of young MM patients using the Canadian Myeloma Research Group (CMRG) database. We included 493 patients ≤ 50 years old diagnosed with MM or plasma cell leukemia without concurrent amyloidosis or POEMS syndrome from January 1, 2010, to July 1, 2022.ResultsThe median age was 46 years old (range: 25.6–50). Most patients fell into the R‐ISS II category (72.7%), and 24.1% had high‐risk cytogenetics. The majority of patients (89.9%) received a proteasome inhibitor‐based first‐line treatment, 92.1% received a stem cell transplant, and 65.6% had maintenance therapy post–autologous stem cell transplant (ASCT). Median follow‐up from initial treatment to patients' last follow‐up was 48.5 (range: 0–155) months. Median progression‐free survival (PFS) was 45.0 months (95% CI: 40.2–50.0). Maintenance therapy post‐ASCT improved median PFS to 52.3 months (95% CI: 43.1–68.2), compared to 23.6 months (95% CI: 20.0–34.8) without maintenance [p < 0.001].ConclusionAlthough the overall survival has not yet been reached in this young population, our reported median PFS of only 45 months highlights the urgent need to develop innovative treatments to induce more profound and durable responses.

show abstract

Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registry

Cited by 4 publications

References 4 publications

Non-secretory myeloma in young man mimicking the Gorham disease: case report and the literature review

Non-secretory myeloma in young man mimicking the Gorham disease: case report and the literature review

Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up‐front autologous stem cell transplant

Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study

Contact Info

Product

Resources

About